Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Trial Profile

A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACP 01 (Primary)
  • Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Sponsors Hemostemix
  • Most Recent Events

    • 26 Jan 2020 According to a Hemostemix Inc. media release, company anticipates that it will conduct a futility analysis for potentially stopping enrolment in the clinical trial when 42 subjects have completed at least 26 weeks of follow-up.
    • 30 Apr 2019 Status changed from recruiting to suspended.
    • 27 Apr 2018 According to a Hemostemix Inc. media release,The Company recently announced that it received FDA approval in the United States in addition to Health Canada approval for its clinical trial in Canada.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top